secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2023-03-07T23:59:59+00:00
Accession:  0000950170-23-006385
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus Q4 net loss $10.9M; COO Craig Millian departing; CRB-701 ADC licensed from CSPC
--------------------------------------------------------------------------------

- Net loss for Q4 2022 was $10.9M ($2.61/diluted share); FY2022 net loss $42.3M ($10.15/diluted share).
- Cash and investments of $59.2M as of Dec 31, 2022, expected to fund operations through Q2 2024.
- COO Craig Millian resigned effective April 14, 2023 to pursue other opportunities.
- Licensed CRB-701 (Nectin-4 ADC) from CSPC; Phase 1 dose escalation ongoing in China for advanced solid tumors.
- CRB-601 (anti-αvβ8 mAb) IND submission scheduled for H2 2023; first patient expected by end of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017023006385/0000950170-23-006385-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017023006385/crbp-20230303.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-006385

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer